Navigation Links
Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
Date:6/16/2011

mpleted assessment of GP against a long-acting muscarinic antagonist, Spiriva."

Pearl's new Phase 2 studies follow the successful conclusion of the Company's first Phase 2b study, in which patients administered PT003 experienced superior bronchodilation compared to those administered the individual components, PT001 and PT005, in a head-to-head comparison following the expectations set under FDA's combination rule. Further, PT003 also showed superior bronchodilation compared to active comparators, Spiriva® HandiHaler® and Foradil® Aerolizer®. This assessment was based on the primary endpoint of FEV1 (AUC0-12) after one week, as well as secondary endpoints, peak FEV1 after one and seven days, and trough FEV1. Primary and secondary endpoints from this Phase 2b study were presented in May 2011 at the American Thoracic Society annual meeting. This poster may be downloaded from the Publications page of the Pearl website. The five studies in Pearl's Phase 2 program are fully funded by proceeds of the Company's 2010 Series C financing.

Since its inception in 2007, Pearl has completed four early stage clinical trials on PT003, PT001 and PT005, along with a suite of non-clinical toxicology studies, and generated comprehensive data on product design and robustness, to boost its confidence in the scientific and clinical merit of the four new Phase 2b studies.

About COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inha
'/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
8. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
9. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
10. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
11. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Data Provides Ophthalmologists Critical Insight on Novel Beta ... Radiation Epiretinal Therapy, ... a one-year feasibility study of the company,s novel beta,radiation epiretinal therapy ... Annual Meeting of the American Academy of,Ophthalmology in New Orleans, Louisiana. ...
... American College of Rheumatology Annual Congress -, ... BMY ) today announced the results of three ... showed ORENCIA(R) (abatacept) improved daily,activity participation, such as ... sleep quality in adult rheumatoid arthritis,(RA) patients who ...
Cached Medicine Technology:NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 2NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 2Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 4Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 5Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 6Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 7Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 8Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 9
(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...
... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...
... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...
... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...
... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...
... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...
Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2Health News:Doctors Can Influence Patients to Lose Weight: Studies 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...
Medicine Products: